THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, October 27, 2020
The mounting pressure on pharma companies to improve their return on investments will drive the firms to outsource operations.
FREMONT, CA: The pharma industry has witnessed dynamic changes over the last few years. The increasing importance of Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), rapid adoption of innovative technologies, and increasing pressure from authorities worldwide to mitigate the burden are some of the themes that influenced the pharma industry. The most daunting issues the industry has been facing are the massive R&D spend and declining return on investments. Combined it with pressure from regulating bodies on drug pricing and the demand to enhance productivity and efficiency throughout the value chain.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
[vendor_logo_first]Outsourcing has been a popular method for pharma companies to enhance operational efficiencies, win geographical presence, and improve therapeutic expertise and on-demand services. This trend is estimated to grow at a compound annual growth rate of about 7 percent. Outsourcing helps pharma firms to save on resource cost, infrastructure cost, and other overhead expenses. Although cost mitigation remains the vital reason for outsourcing many functions across the industry, several pharma firms are shifting to outsourcing. In the present market, pharma companies attribute enhanced quality and reduced time-to-market as the motivations for outsourcing their business functions to CROs, CMOs, and CSOs.
With consolidation in the market, these outsourcing firms will compete to become strategic partners of pharmaceutical companies and not just stay content being a service provider. Pharma firms now prefer long-term collaborations with a few vendors, which is a significant shift away from previous models. The combining of services is expected to improve the efficiency of outsourcing by offering end-to-end solutions. This will reduce the cost of pharma companies and give them better control visibility and flexibility. The industry expects bundled solutions in trial planning, conduct, and reporting solutions in the R&D space.
With pharmaceutical firms acutely aware of the requirement to be flexible, cutting-edge, and access new skill sets, there are several benefits to seeking an outsourcing solution for a range of operations. This gives companies the ability to rapidly scale resources up and down, access skills and expertise in a data-rich environment, and positively impact business operations.
See Also: Top Pharma and Life Sciences Tech Solution Companies
More in News